eTable 1. Drop-out analysis—baseline survey data.
| Characteristics | Drop-outs (N = 99) | Completers (N = 431) | p value | |||
| Valid N | N (%)/M (SD) | Valid N | N (%)/M (SD) | |||
| Sex | Female | 99 | 65 (65.7%) | 431 | 246 (57.1%) | 0.118 |
| Age in years | 18–30 | 99 | 22 (22.2%) | 431 | 75 (17.4%) | 0.343 |
| 31–40 | 26 (26.3%) | 92 (21.3%) | ||||
| 41–50 | 24 (24.2%) | 116 (26.9%) | ||||
| 51–64 | 27 (27.3%) | 148 (34.3%) | ||||
| Employment status | Working full-time | 99 | 80 (80.8%) | 431 | 326 (75.6%) | 0.207 |
| School education (in years) | Up to 9 | 93 | 8 (8.6%) | 429 | 52 (12.1%) | 0.501 |
| 10–11 | 39 (41.9%) | 188 (43.8%) | ||||
| 12–13 | 46 (49.5%) | 189 (44.1%) | ||||
| Residential area | Core cities | 99 | 33 (33.3%) | 430 | 136 (31.6%) | 0.614 |
| Dense surrounding areas | 36 (36.4%) | 182 (41.3%) | ||||
| Rural surrounding areas | 14 (14.1%) | 60 (14.0%) | ||||
| Rural areas | 16 (16.2%) | 52 (12.1%) | ||||
| Diagnosis | Crohn’s disease | 99 | 59 (59.6%) | 431 | 229 (53.1%) | 0.418 |
| Ulcerative colitis | 37 (37.4%) | 192 (44.5%) | ||||
| Indeterminate colitis | 3 (3.0%) | 10 (2.3%) | ||||
| Disease duration | In years | 99 | 11.4 (9.1) | 426 | 14.0 (10.2) | 0.022 |
| Course of disease “during the preceeding years“ |
In remission | 99 | 11 (11.1%) | 423 | 53 (12.5%) | 0.148 |
| Alternating relapse/remission | 42 (42.4%) | 218 (51.5%) | ||||
| Constantly/increasingly active | 46 (46.5%) | 152 (35.9%) | ||||
| Disease activity during the past 7 days (GIBDI*) |
Remission (0–3) | 93 | 22 (23.7%) | 394 | 113 (28.7%) | 0.301 |
| Mild (4–7) | 44 (47.3%) | 187 (47.5%) | ||||
| Moderate (8–11) | 21 (22.6%) | 83 (21.1%) | ||||
| Severe (≥ 12) | 6 (6.5%) | 11 (2.8%) | ||||
| Surgery for IBD | Ever (yes) | 98 | 34 (34.7%) | 429 | 134 (31.2%) | 0.507 |
| Rehabilitation for IBD | Ever (yes) | 99 | 33 (33.3%) | 431 | 173 (40.1%) | 0.210 |
| Medication intake during the past 3 months(yes) | 5-aminosalicylates | 99 | 52 (52.5%) | 431 | 231 (53.6%) | 0.847 |
| Corticosteroids | 42 (42.4%) | 184 (42.7%) | 0.961 | |||
| Immunosuppressants | 26 (26.3%) | 115 (26.7%) | 0.932 | |||
| Biologic agents | 37 (37.4%) | 166 (38.5%) | 0.833 | |||
| None | 6 (6.1%) | 16 (3.7%) | 0.291 | |||
| Number of IBD-related specialist visits |
Past 12 months | 99 | 20.1 (18.2) | 431 | 18.6 (16.2) | 0.409 |
| Satisfaction with IBD care | 0–10 | 99 | 5.8 (2.5) | 430 | 6.3 (2.5) | 0.107 |
| Limitation in social participation (IMET) | 0–90 | 98 | 36.4 (18.6) | 430 | 33.8 (18.9) | 0.212 |
| Self-management (heiQ scales) (1–4) |
Self-monitoring and insight | 97 | 3.0 (0.4) | 422 | 3.0 (0.5) | 0.519 |
| Constructive attitudes | 99 | 3.1 (0.5) | 428 | 3.1 (0.5) | 0.824 | |
| Emotional well-being (the higher, the poorer) | 98 | 2.5 (0.7) | 429 | 2.4 (0.7) | 0.090 | |
| Level of being informed about IBD (NRS) | 0–10 | 99 | 6.3 (2.6) | 431 | 6.7 (2.4) | 0.217 |
| Current health-related quality of life (EQ-VAS) | 0–100 | 97 | 60.0 (18.8) | 429 | 62.0 (16.3) | 0.282 |
| Vitality (SF-36) | 0–100 | 98 | 32.7 (16.8) | 430 | 36.1 (17.5) | 0.081 |
| Psychological distress (PHQ-4) | 0–12 | 97 | 4.8 (2.6) | 428 | 4.4 (2.7) | 0.138 |
| Sick days taken off from work in the past 3 months | 0–90 | 97 | 13.3 (21.2) | 422 | 11.3 (17.1) | 0.325 |
| Negative subjective employment prognosis |
SPE ≥ 2 | 99 | 50 (50.5%) | 429 | 225 (52.4%) | 0.727 |
IFW, incapacity for work; IBD, inflammatory bowel disease; EQ-VAS, EuroQuol Visual Analogue Scale; GIBDI, German Inflammatory Bowel Disease Activity Index (*cannot be calculated for patients with stoma or indeterminate colitis); heiQ, Health Education Impact Questionnaire; IMET, index for measuring limitations of participation (“Index zur Messung von Einschränkungen der Teilhabe”); M, mean; N, number of valid cases; NRS, numerical rating scale; PHQ-4, Patient Health Questionnaire (short form with 4 items); SD, standard deviation; SF-36, Short Form 36 questionnaire; SPE, subjective prognostic employment scale